Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
Public ClinicalTrials.gov record NCT00915018. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Two-Arm Study Of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel As First-Line Treatment For ErbB-2-Positive Locally Recurrent Or Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is investigating the effects of an experimental drug (neratinib) in combination with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of women who have not received previous treatment for erbB-2-positive locally recurrent or metastatic breast cancer. The study will compare the effectiveness of each regimen in shrinking tumors and extending the lives of women with erbB-2 (HER2) positive breast cancer. The study will also compare the safety of the two regimens and as well as the quality of life of subjects receiving either regimen.
Study identification
- NCT ID
- NCT00915018
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 479 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 21, 2009 (Actual)
- Primary completion
- Aug 2013 (Actual)
- Completion
- Jun 28, 2018 (Actual)
- Last update posted
- Aug 22, 2018
2009 – 2018
United States locations
- U.S. sites
- 36
- U.S. states
- 19
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ventura County Hematology-Oncology Specialists | Oxnard | California | 93030 | — |
| Redwood Regional Medical Group | Santa Rosa | California | 95403 | — |
| Cancer Center of Central Connecticut | Plainville | Connecticut | 06062 | — |
| Palm Beach Institute of Hematology and Oncology | Boynton Beach | Florida | 33435 | — |
| North Broward Medical Center Cancer Center | Deerfield Beach | Florida | 33064 | — |
| Broward General Medical Center | Fort Lauderdale | Florida | 33316 | — |
| Mid Florida Cancer Centers | Orange City | Florida | 32763 | — |
| Florida Cancer Research Institute | Plantation | Florida | 33324 | — |
| Hematology Oncology Associates of Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| Phoebe Cancer Center | Albany | Georgia | 31701 | — |
| Dublin Hematology and Oncology Care | Dublin | Georgia | 31021 | — |
| Clintell | Skokie | Illinois | 60077 | — |
| Presence Hematology and Oncology | Skokie | Illinois | 60077 | — |
| Springfield Clinic | Springfield | Illinois | 62703 | — |
| CHRISTUS St. Frances Cabrini Hospital | Alexandria | Louisiana | 71301 | — |
| Hematology Oncology Services | Metairie | Louisiana | 70006 | — |
| Park Nicollet Institute | Saint Louis Park | Minnesota | 55426 | — |
| Missouri Cancer Associates | Columbia | Missouri | 65201 | — |
| St. John's Medical Research Institute | Springfield | Missouri | 65807 | — |
| Washington University School of Medicine Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| The Valley Hospital, Luckow Pavilion Office of Oncology Clinical Trials | Paramus | New Jersey | 07652 | — |
| Gaston Hematology and Oncology Associates | Gastonia | North Carolina | 28054 | — |
| Summa Health System Hospitals | Akron | Ohio | 44304-1619 | — |
| Warren Cancer Research Foundation | Tulsa | Oklahoma | 74104 | — |
| Samaritan Hematology and Oncology Consultants | Corvallis | Oregon | 97330 | — |
| Pawtucket Memorial Hospital | Pawtucket | Rhode Island | 02860 | — |
| Medical University of South Carolina Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| Santee Hematology Oncology | Sumter | South Carolina | 29150 | — |
| Tenessee Cancer Specialists | Knoxville | Tennessee | 37909 | — |
| Family Cancer Care | Memphis | Tennessee | 38120 | — |
| Texas Oncology | Bedford | Texas | 76022 | — |
| El Paso Cancer Treatment Center | El Paso | Texas | 79902 | — |
| Texas Oncology-Allison Cancer Center | Midland | Texas | 79701 | — |
| Southlake Oncology | Southlake | Texas | 76092 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| Charleston Area Medical Center, Health, Education, and Research Institute | Charleston | West Virginia | 25304 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 159 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00915018, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 22, 2018 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00915018 live on ClinicalTrials.gov.